NEW YORK U.S. drug maker Pfizer Inc's $160 billion agreement to acquire Botox maker Allergan Plc was on the brink of being abandoned on Tuesday, after the U.S. Treasury issued new rules on how tax "inversion" deals can be structured.
Allergan's shares were hit considerably hard on Tuesday, showing how the rules that were issued on Monday targeted the biggest inversion attempted to date. The federal government has grappled with a wave of recent inversions by U.S. companies seeking to slash their tax bills by redomiciling overseas...
01:45 Japanese shares fall 1% as yen strengthens, Samsung presser announcements ahead18
19:39 $1M '100 percent Swiss Made' watch made of real Swiss cheese16
21:52 Netflix nears 94 million subscribers 10 years after streaming launch20
16:50 Goldman Sachs, Citigroup earnings confirm Trump effect on banks19